SEC Form 4 · accession 0001513162-17-000212
Anixa Biosciences Inc · ANIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Catelani
Officer — Chief Operating Officer
Period of report
Jul 6, 2017
Accepted (ET)
Jul 25, 2017 · 4:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000715446
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F2 | $0.96 | Jul 6, 2017 | A | 200,000 | A | — | Jul 6, 2027 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1Right-To-Buy, pursuant to the ITUS Corporation 2010 Share Incentive Plan.
- F2The option vests and become exercisable as follows: 25% on July 6, 2018 and the remainder over twelve (12) equal quarterly installments beginning October 31, 2018.